7.3 Drug-Nutrient Interactions & Enteral Medication Delivery

7.3 Drug-Nutrient Interactions & Enteral Medication Delivery

Clinical Core: Delivering medications through enteral feeding tubes is fraught with pharmacotherapeutic and mechanical hazards. Altering dosage forms by crushing modified-release or enteric-coated tablets precipitates catastrophic dose dumping, severe toxicity, or drug inactivation. Furthermore, physical chelation, formula protein binding, and vehicle-induced osmotic diarrhea (from excipients like sorbitol) undermine clinical efficacy. Nutrition support clinicians must enforce strict ASPEN medication delivery protocols: flushing between separate medications, honoring drug-holding intervals, and selecting appropriate formulations.

---

Core Dosage Form Principles: The "Do Not Crush" Rules

Oral solid dosage forms are engineered with specialized chemical coatings, polymeric matrices, and osmotic delivery systems that govern drug dissolution, site-specific absorption, and steady-state kinetics. Crushing a solid dosage form fundamentally alters its pharmacokinetics and can produce lethal consequences.

               ┌────────────────────────────────────────────────────────┐
               │               "DO NOT CRUSH" DOSAGE FORMS             │
               └───────────────────────────┬────────────────────────────┘
                                           │
         ┌────────────────────────┬────────┴────────┬────────────────────────┐
         ▼                        ▼                 ▼                        ▼
┌─────────────────┐      ┌─────────────────┐ ┌────────────────┐     ┌────────────────┐
│ Modified-Release│      │ Enteric-Coated  │ │ Cytotoxic &    │     │ Sublingual /   │
│ (ER, XR, SR, CD)│      │      (EC)       │ │ Hazardous Drugs│     │ Buccal Tablets │
├─────────────────┤      ├─────────────────┤ ├────────────────┤     ├────────────────┤
│• Lethal "DOSE   │      │• Acid-labile    │ │• Aerosolized   │     │• Extensive     │
│  DUMPING"       │      │  degradation    │ │  hazardous     │     │  hepatic first-│
│• Acute toxicity │      │• Gastric mucosal│ │  particulates  │     │  pass effect   │
│  followed by    │      │  irritation     │ │• Risk to staff │     │• Negligible    │
│  zero efficacy  │      │• Severe clumping│ │• Requires CSTD │     │  bioavailabil. │
└─────────────────┘      └─────────────────┘ └────────────────┘     └────────────────┘

1. Modified-Release Formulations

• Nomenclature: Designated by suffixes including ER / XR (extended-release), XL (extended-length), SR (sustained-release), CR (controlled-release), CD (controlled-delivery), LA (long-acting), TR (time-release), or OROS (osmotic-controlled release oral delivery system).
• Mechanism of Danger — Dose Dumping: These formulations contain a full 12- to 24-hour therapeutic payload within a single tablet, engineered to release active drug slowly across the GI tract. Crushing destroys the release-retarding matrix or semi-permeable membrane. The entire 24-hour dose dissolves and absorbs immediately—a phenomenon termed "dose dumping".
• Clinical Outcome: Rapid peak plasma concentrations spike to toxic or fatal levels (e.g., severe hypotension and bradycardia from crushed diltiazem CD or nifedipine XL; fatal respiratory depression from crushed oxycodone CR or morphine ER), followed by a prolonged period of subtherapeutic plasma levels where the patient receives zero therapeutic benefit.

2. Enteric-Coated (EC) Formulations

• Mechanism of Action: Formulated with an acid-resistant polymeric coating (e.g., cellulose acetate phthalate) that remains insoluble in the acidic environment of the stomach ($pH < 5.5$) but dissolves rapidly in the neutral-to-alkaline duodenum ($pH > 6.0$).
• Consequences of Crushing:
  • Acid Inactivation: Acid-labile drugs (e.g., proton pump inhibitors such as omeprazole, pantoprazole) are degraded and inactivated by gastric hydrochloric acid before reaching systemic circulation, rendering therapy useless.
  • Gastric Mucosal Injury: Medications that are directly corrosive to the stomach lining (e.g., enteric-coated aspirin, potassium chloride, bisacodyl) cause acute chemical gastritis, mucosal erosion, and peptic ulcer bleeding when crushed.
  • Tube Occlusion: Crushed enteric coatings become sticky and gelatinous upon contact with water or formula, adhering tenaciously to the internal feeding tube lumen and causing intractable clogging.

3. Cytotoxic, Teratogenic, and Hazardous Drugs

Crushing hazardous pharmaceuticals (e.g., antineoplastic chemotherapy agents such as hydroxyurea, methotrexate, tamoxifen, or finasteride) generates airborne aerosolized micro-particles. Inhaling or absorbing these particles exposes nursing staff, pharmacists, and caregivers to significant mutational, teratogenic, and carcinogenic risks. Closed-system drug transfer devices (CSTDs) or liquid commercial formulations must be utilized.

4. Sublingual and Buccal Dosage Forms

Sublingual (e.g., nitroglycerin SL) and buccal formulations are engineered for direct transmucosal absorption into the rich sublingual venous plexus, bypassing the portal vein and avoiding first-pass hepatic metabolism. Swallowing these tablets or instilling them down an enteral feeding tube shunts the drug directly into the portal circulation, where high first-pass hepatic extraction renders the medication clinically inactive.

---

Liquid Dosage Forms: Osmolality and Sorbitol Hazards

While converting from solid tablets to commercial liquid elixirs, syrups, or suspensions seems intuitive for tube feeding, liquid dosage forms harbor substantial clinical pitfalls.

Hyperosmolality and Dilution

Commercial liquid formulations are typically hypertonic, exhibiting osmolalities between 1,000 and 3,500 mOsm/kg H₂O due to concentrated solubilizing vehicles (sucrose, glycerin, propylene glycol, polyethylene glycol). Instilling an undiluted hyperosmolar elixir directly into the stomach—or worse, directly into the small intestine via a jejunostomy—draws massive volumes of free water into the intestinal lumen, triggering acute abdominal cramping, distension, nausea, and osmotic diarrhea. All liquid medications must be diluted with at least 10 to 30 mL of sterile water prior to enteral tube administration.

The Sorbitol Burden

Sorbitol is an inert, non-absorbable sugar alcohol widely used as a sweetening and stabilizing excipient in liquid elixirs (e.g., liquid acetaminophen, theophylline, furosemide, guaifenesin, and potassium chloride solutions).

• Thresholds for Toxicity: Ingesting 5 to 10 grams of sorbitol daily produces abdominal bloating, flatulence, and mild cramping; cumulative daily intakes exceeding 10 to 20 grams provoke severe osmotic diarrhea.
• Clinical Rule: In any enterally fed patient who develops unexplained watery diarrhea, calculate the cumulative daily sorbitol load across all prescribed liquid medications. If the total exceeds 10 g/day, consult pharmacy to substitute with crushed immediate-release tablets or intravenous alternatives.

---

High-Impact Enteral Drug-Nutrient Interactions

                  ┌─────────────────────────────────────────────────────────┐
                  │           CATION CHELATION OF FLUOROQUINOLONES          │
                  └────────────────────────────┬────────────────────────────┘
                                               │
                  ┌────────────────────────────┴────────────────────────────┐
                  ▼                                                         ▼
    ┌───────────────────────────┐                             ┌───────────────────────────┐
    │ Oral Fluoroquinolone      │                             │ Multivalent Cations       │
    │ (Ciprofloxacin Molecule)  │                             │ (Ca²⁺, Mg²⁺, Fe²⁺, Zn²⁺)  │
    └─────────────┬─────────────┘                             └─────────────┬─────────────┘
                  │                                                         │
                  └────────────────────────────┬────────────────────────────┘
                                               │
                                               ▼
                               ┌───────────────────────────────┐
                               │ Insoluble Chelation Complex   │
                               │ (Precipitated in Gut Lumen)   │
                               ├───────────────────────────────┤
                               │• Molecule becomes unabsorbable│
                               │• Bioavailability drops 30-70% │
                               │• Result: Clinical treatment   │
                               │  failure, bacterial resistance│
                               └───────────────────────────────┘

---

The ASPEN Safe Enteral Medication Administration Protocol

To ensure patient safety, prevent physical tube occlusion, avoid chemical drug incompatibilities, and preserve drug bioavailability, the American Society for Parenteral and Enteral Nutrition (ASPEN) has established an evidence-based clinical medication administration protocol.

                     ┌─────────────────────────────────────────┐
                     │   ASPEN ENTERAL MEDICATION PROTOCOL     │
                     └────────────────────┬────────────────────┘
                                          │
                                          ▼
                     ┌─────────────────────────────────────────┐
                     │ 1. STOP ENTERAL FEEDING                 │
                     │    (Honor 1-2 hr hold if required)      │
                     └────────────────────┬────────────────────┘
                                          │
                                          ▼
                     ┌─────────────────────────────────────────┐
                     │ 2. INITIAL FLUSH                        │
                     │    Flush tube with 15 to 30 mL water    │
                     └────────────────────┬────────────────────┘
                                          │
                                          ▼
                     ┌─────────────────────────────────────────┐
                     │ 3. ADMINISTER SINGLE MEDICATION         │
                     │    • Administer each drug SEPARATELY    │
                     │    • NEVER co-mingle drugs in a slurry! │
                     └────────────────────┬────────────────────┘
                                          │
                                          ▼
                     ┌─────────────────────────────────────────┐
                     │ 4. INTERMEDIATE FLUSH                   │
                     │    Flush with 15 to 30 mL water between │
                     │    each individual medication           │
                     └────────────────────┬────────────────────┘
                                          │
                                          ▼
                     ┌─────────────────────────────────────────┐
                     │ 5. FINAL FLUSH & RESUME                 │
                     │    • Flush with 15 to 30 mL water       │
                     │    • Resume feeds (or honor hold window)│
                     └─────────────────────────────────────────┘

Step-by-Step Clinical Procedure

1. Verify Tube Anatomy & Medication Route: Confirm feeding tube location (gastric vs. duodenal vs. jejunal). Certain medications require gastric acid for dissolution (e.g., ketoconazole, iron salts) and cannot be absorbed efficiently if administered directly into the jejunum.
2. Temporarily Stop the Feeding Infusion: Pause the enteral pump.
3. Deliver Initial Flush: Flush the feeding tube with 15 to 30 mL of sterile water to clear all residual formula from the lumen.
4. Administer Each Medication Separately:
   • Each solid medication must be finely crushed into a uniform powder and dissolved in 15 to 30 mL of sterile water in its own separate cup.
   • The Absolute Rule Against Co-Mingling: Clinicians must never crush multiple different tablets together into a single combined syringe or "slurry". Mixing multiple crushed drugs together creates unpredictable physicochemical incompatibilities, physical precipitates, altered dissolution curves, and extreme tube clogging hazards.
5. Deliver Intermediate Water Flushes: Flush the tube with 15 to 30 mL of sterile water between each separate medication.
6. Deliver Final Flush: Flush the tube with 15 to 30 mL of sterile water after administering the final medication.
7. Resume Enteral Nutrition: Restart the feeding infusion immediately, or observe the mandatory 1- to 2-hour holding window for interacting medications (e.g., phenytoin, ciprofloxacin, levothyroxine).